BlueCross BlueShield of Tennessee Medical Policy Manual

Corneal Collagen Cross-Linking

DESCRIPTION

Corneal collagen cross-linking (CXL) is performed with the photosensitizer riboflavin (vitamin B2) and ultraviolet-A (UVA) irradiation. A common CXL protocol removes about 8 mm of the central corneal epithelium under topical anesthesia to allow better diffusion of the photosensitizer riboflavin into the stroma. Following de-epithelialization, a solution with riboflavin is applied to the cornea (every 1-3 minutes for 30 minutes) until the stroma is completely penetrated. The cornea is then irradiated with UVA at a maximal wavelength to allow for absorption by riboflavin. The interaction of riboflavin and UVA causes the formation of reactive oxygen species, leading to additional covalent bonds (cross-linking) between collagen molecules that results in stiffening of the cornea.

CXL is being evaluated primarily for corneal stabilization in patients with progressive corneal thinning such as keratoconus. It has also been evaluated in the treatment of keratitis and ectasia.

Keratoconus is characterized by thinning of the corneal surface and the development of a cone-shaped bulge . This bulging causes refractive errors and deterioration of visual acuity. Keratoconus can be idiopathic or iatrogenic and may be seen as a result of laser in situ keratomileusis (LASIK).

POLICY  

See also:  Intrastromal Corneal Ring Segments (ICRS) for Vision Correction

IMPORTANT REMINDERS

ADDITIONAL INFORMATION

No UVA devices have received clearance or pre-market approval for the treatment of keratoconus in the U.S. Phase III clinical trials evaluating safety and efficacy are on-going.

SOURCES

American Academy of Ophthalmology. (September, 2007). Refractive errors and refractive surgery preferred practice pattern. Retrieved July 6, 2012 from http://one.aao.org/printerfriendly.aspx?cid=e6930284-2c41-48d5-afd2-631dec586286#references.

BlueCross BlueShield Association. Medical Policy Reference Manual. (3:2012). Corneal collagen cross-linking (9.03.28). Retrieved July 6, 2012 from BlueWeb. (13 articles and/or guidelines reviewed)

Hovakimyan, M., Guthoff, R., & Stachs, O. (2012). Collagen cross-linking: Current status and future trends. Journal of Ophthalmology, Epub 2012.

Kanellopoulos, A. (2012). Long term results of a prospective randomized bilateral eye comparison trial of higher fluence, shorter duration ultraviolet A radiation, and riboflavin collagen cross linking for progressive keratoconus. Clinical Ophthalmology, 2012 (96), 97-101. (Level 3 Evidence)

Leccisotti, A., Aslanides, J., Moore, J, & shah, S. (2012). Keratoconus and keratoectasia: Advancements in diagnosis and treatment. Journal of Ophthalmology, Epub 2012.

Makdoumi, K., Mortensen, J., & Crafoord, S. (October, 2011). Corneal cross-linking for the treatment of keratitis. Cataract and Refractive Surgery Today Europe. Retrieved July 10, 2012 from http://bmctoday.net/crstodayeurope/pdfs/CRSTE1011_rs_makdoumi.pdf.

National Institute for Health and Clinical Excellence. (2009, November). Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus. Retrieved July 6, 2012 from www.nice.org.uk/topic.

National Institute of Health. (June 2012). Vision research: Needs, gaps, and opportunities. Retrieved July 6, 2012 from: www.nei.nih.gov/strategicplanning/VisionResearchNeedsGapsandOpportunities.doc - 249k - 07-05-20122012-07-05.

Sauer, A., Letscher-Bru, V., Speeg-Schatz, C., Touboul, D., Colin, J., Candolfi, E., et al. (2010). In vitro efficacy of antifungal treatment using riboflavin/UV-A (365 nm) combination and amphotericin B. Investigative Ophthalmology and Visual Science, 51 (8), 3950-3953. (Level 4 Evidence - Independent study)

ORIGINAL EFFECTIVE DATE:  11/10/2012

MOST RECENT REVIEW DATE:  11/10/2012  

ID_BA

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.